CaseBioscience®, a registered biotechnology company, is a scholar in advanced media, biopreservation solutions and cGMP-compliant mainly for cell therapy, IVF/ART, regenerative medicine and cell therapy. The company continues its business through its Stem cell Research and Assisted Reproductive Technology, which offers apt cell therapy and IVF tools. The best of its services is its small batch manufacturing and emerging prototyping.
At the Advanced Therapies Week (ATW) 2026, CaseBioscience® will be rolling the curtain up for CaseCryo® CTG DMSO, a future stored cryopreservation solution. This solution will be a boost to clinical cell therapy development. Alongside will be ramping up one more solution for CaseStor®HSS Hypothermic Storage Solution, especially for balanced hypothermic storage of tissues and cells.
These new launches are a boon and confidence booster for the company’s biopreservation portfolio. CaseBioscience is sincerely reciprocating in its dedication to serving the best of the best solutions for fragile and careful cell therapy movement. At the ATW event 2026, cell therapy manufacturers and developers are called to come together learn in-depth about CaseStor® HSS Hypothermic Storage Solution and CaseCryo® CTG DMSO.
The CaseStor® HSS and CaseCryo® CTG DMSO can be trusted with the promise of the company for its cGMP-based quality systems. The manufacturing is performed at the FDA-certified facility, which obeys and follows ART-driven quality principles. Whereas, CaseStor® HSS contributes to the advanced post-storage extension of MSCs, T cells and hPSCs, and CaseCryo® CTG DMSO pumps up the recovery rate and extends the potential of hPSCs and T cells in competition with all popular solutions, proving its suitability.
Following this, the Drug Master Files (DMFs) are registered for both products for standing by the regulatory alignment and contribute to clinical development. Further, at ATW 2026, the healthcare leaders can have a dive into the knowledge of these solutions and the company’s brave visions towards biopreservation (cell therapy).
Based on the solutions, qualification, structure, and assessment of this biopreservation proves to be in favor of good cell performance and health. This is a strength and a new frame to the existing cell therapy research targeted products of the company, which will bolster and upgrade the alternative cryoprotectant strategies. This will sharpen the focus on the cell therapy applications and might give approaches a hint of action for further developmental procedure.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
